Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts sold 18,334 shares of the company’s stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $56.60, for a total transaction of $1,037,704.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Ryan J. Watts also recently made the following trade(s):
- On Thursday, February 11th, Ryan J. Watts sold 9,473 shares of Denali Therapeutics stock. The stock was sold at an average price of $70.30, for a total transaction of $665,951.90.
Shares of Denali Therapeutics stock opened at $52.43 on Thursday. The stock has a market cap of $6.34 billion, a price-to-earnings ratio of -23.72 and a beta of 2.00. The firm’s 50-day moving average is $61.08 and its two-hundred day moving average is $62.42. Denali Therapeutics Inc. has a 1 year low of $17.74 and a 1 year high of $93.94.
Several large investors have recently made changes to their positions in DNLI. Crestline Management LP raised its position in shares of Denali Therapeutics by 59.5% in the 4th quarter. Crestline Management LP now owns 19,462,500 shares of the company’s stock worth $339,037,000 after acquiring an additional 7,260,866 shares in the last quarter. Baillie Gifford & Co. grew its stake in Denali Therapeutics by 12.6% in the fourth quarter. Baillie Gifford & Co. now owns 12,190,256 shares of the company’s stock valued at $1,021,056,000 after purchasing an additional 1,363,078 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Denali Therapeutics by 48.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,464,826 shares of the company’s stock worth $541,494,000 after purchasing an additional 2,103,851 shares in the last quarter. BlackRock Inc. raised its holdings in Denali Therapeutics by 4.8% in the fourth quarter. BlackRock Inc. now owns 6,376,078 shares of the company’s stock worth $534,062,000 after purchasing an additional 290,761 shares in the last quarter. Finally, Credit Suisse AG lifted its position in shares of Denali Therapeutics by 1,626.2% during the fourth quarter. Credit Suisse AG now owns 1,402,750 shares of the company’s stock valued at $117,494,000 after buying an additional 1,321,486 shares during the last quarter. Institutional investors and hedge funds own 68.15% of the company’s stock.
A number of research analysts have recently commented on the company. TheStreet raised Denali Therapeutics from a “d+” rating to a “c” rating in a research note on Friday, February 26th. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a research report on Friday, January 8th. They issued a “positive” rating on the stock. Zacks Investment Research upgraded Denali Therapeutics from a “sell” rating to a “hold” rating and set a $66.00 target price for the company in a research report on Friday, February 19th. Morgan Stanley upped their price target on shares of Denali Therapeutics from $75.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, December 16th. Finally, Cantor Fitzgerald upgraded shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating and set a $105.00 price objective for the company in a report on Wednesday, February 10th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $74.63.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease.
Further Reading: Pattern Day Trader
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.